Loading...
OTCM
DMKPQ
Market cap0kUSD
Apr 01, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-100.00%
Name

Adamis Pharmaceuticals Corp

Chart & Performance

D1W1MN
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
226.32%
Rev. gr., 5y
-18.31%
Revenues
5m
+115.34%
1,620,0002,596,37712,835,0002,660,05800660,000290,288000006,473,97813,073,25915,086,64322,113,86916,527,3972,208,6804,756,078
Net income
-26m
L-24.28%
-13,532,000-28,154,062-5,008,0009,671,805-1,927,061-1,533,871-5,210,000-6,559,623-6,979,813-4,915,295-7,194,792-8,155,880-13,571,997-19,437,252-25,538,980-39,006,782-29,306,769-49,391,089-34,600,353-26,199,406
CFO
-26m
L-31.45%
-12,507,000-13,600,923-16,729,000-5,042,484-1,937,218-1,197,490-4,990,000-1,998,637-4,347,277-3,345,859-2,559,009-6,780,120-10,335,578-21,160,267-15,132,575-32,657,549-19,885,668-20,901,360-37,785,297-25,900,506

Profile

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
URL
https://www.adamispharmaceuticals.com/
IPO date
Aug 14, 1995
Employees
11
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,756
115.34%
Cost of revenue
16,567
Unusual Expense (Income)
NOPBT
(11,811)
NOPBT Margin
Operating Taxes
2
Tax Rate
NOPAT
(11,813)
Net income
(26,199)
-24.28%
Dividends
Dividend yield
Proceeds from repurchase of equity
300
BB yield
Debt
Debt current
343
Long-term debt
343
Deferred revenue
178
Other long-term liabilities
165
Net debt
(396)
Cash flow
Cash from operating activities
(25,901)
CAPEX
(680)
Cash from investing activities
3,484
Cash from financing activities
285
FCF
(3,680)
Balance
Cash
1,081
Long term investments
Excess cash
844
Stockholders' equity
(147,246)
Invested Capital
147,124
ROIC
ROCE
9,644.77%
EV
Common stock shares outstanding
2,141
Price
Market cap
EV
EBITDA
(10,328)
EV/EBITDA
Interest
44
Interest/NOPBT